Company intelligence / Profile preview
KM Biologics
Japankmbiologics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
KM Biologics has a long history in vaccine production with commercialized products for both human and veterinary use. The company has contributed significantly to infectious disease control in Japan. No current active clinical trials are registered on ClinicalTrials.gov as of May 2025.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccines (human and veterinary)Blood plasma productsCell culture-derived vaccinesCombination vaccines (e.g., DPT-based)
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
03
Partnerships
Collaborates with companies and universities domestically and internationally for new vaccine development.
Beyond the preview
Go deeper on KM Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KM Biologics.